A randomized, double-blind, parallell-group, controlled study of topical pentane-1,5-diol hydrogel in patients with impetigo

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-000808-14-SE

Enrollment

Registered

2005-02-21

Start date

2005-05-24

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impetigo

Interventions

Product Name: Pentane-1,5-diol Pharmaceutical Form: Cutaneous paste INN or Proposed INN: pentane-1,5-diol CAS Number: 111-29-5 Current Sponsor code: P15D Other descriptive name: 1,5-pentanediol Concen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Males and females; age 2 years or older - Clinical diagnosis of impetigo Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Severe organic disease or other disease which may interfere with the administration or assessment of study medication such as severe immunodeficiency or tumor bearing disease; current use of drugs/preparations which may interfere with the study evaluation. - Pregnant or lactating women or female patients without an ongoing efficient contraceptive method

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine whether topical pentane-1,5-diol hydrogel is efficacious in patients with impetigo.;Secondary Objective: - Reduction of impetigo - Recurrence of impetigo within 1 week ;Primary end point(s): - Successfully treated cases with complete clinical improvement and no positive culture	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026